Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220


A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D).

Lam C, Tan W, Leighton M, Hastings M, Lingaya M, Falcone Y, Zhou X, Xu L, Whorwell P, Walls AF, Zaitoun A, Montgomery A, Spiller R.

Gut. 2016 Jan;65(1):91-9. doi: 10.1136/gutjnl-2015-309122. Epub 2015 Mar 12.


Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.

Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC.

Scand J Gastroenterol. 2012 Oct;47(10):1159-64. Epub 2012 Jul 12.


Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.

Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.

Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44.


A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.

Am J Gastroenterol. 2005 Jan;100(1):115-23.


Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.

Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP.

Aliment Pharmacol Ther. 2011 Aug;34(3):374-83. doi: 10.1111/j.1365-2036.2011.04732.x. Epub 2011 Jun 14.


Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.

Chmielewska-Wilkoń D, Reggiardo G, Egan CG.

World J Gastroenterol. 2014 Sep 14;20(34):12283-91. doi: 10.3748/wjg.v20.i34.12283.


The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.

Tack J, Schumacher K, Tonini G, Scartoni S, Capriati A, Maggi CA; and the Iris-2 investigators.

Gut. 2017 Aug;66(8):1403-1413. doi: 10.1136/gutjnl-2015-310683. Epub 2016 Apr 15.


Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.

Bafutto M, Almeida JR, Leite NV, Costa MB, Oliveira EC, Resende-Filho J.

Arq Gastroenterol. 2013 Oct-Dec;50(4):304-9. doi: 10.1590/S0004-28032013000400012.


Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial.

Lam C, Tan W, Leighton M, Hastings M, Lingaya M, Falcone Y, Zhou X, Xu L, Whorwell P, Walls AF, Zaitoun A, Montgomery A, Spiller RC.

Southampton (UK): NIHR Journals Library; 2015 Mar.


Development of the Diary for Irritable Bowel Syndrome Symptoms to Assess Treatment Benefit in Clinical Trials: Foundational Qualitative Research.

Fehnel SE, Ervin CM, Carson RT, Rigoni G, Lackner JM, Coons SJ; Critical Path Institute Patient-Reported Outcome Consortium’s Irritable Bowel Syndrome Working Group.

Value Health. 2017 Apr;20(4):618-626. doi: 10.1016/j.jval.2016.11.001. Epub 2017 Jan 3.


Randomised controlled trial of mesalazine in IBS.

Barbara G, Cremon C, Annese V, Basilisco G, Bazzoli F, Bellini M, Benedetti A, Benini L, Bossa F, Buldrini P, Cicala M, Cuomo R, Germanà B, Molteni P, Neri M, Rodi M, Saggioro A, Scribano ML, Vecchi M, Zoli G, Corinaldesi R, Stanghellini V.

Gut. 2016 Jan;65(1):82-90. doi: 10.1136/gutjnl-2014-308188. Epub 2014 Dec 22.


Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.

Bafutto M, Almeida JR, Leite NV, Oliveira EC, Gabriel-Neto S, Rezende-Filho J.

Arq Gastroenterol. 2011 Jan-Mar;48(1):36-40.


Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.

Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A.

Aliment Pharmacol Ther. 2011 Jun;33(12):1311-21. doi: 10.1111/j.1365-2036.2011.04656.x. Epub 2011 Apr 20.


Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.

Rivkin A, Rybalov S.

Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11. Review.


Effects of two natural medicine formulations on irritable bowel syndrome symptoms: a pilot study.

Hawrelak JA, Myers SP.

J Altern Complement Med. 2010 Oct;16(10):1065-71. doi: 10.1089/acm.2009.0090.


Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

Lembo AJ, Olden KW, Ameen VZ, Gordon SL, Heath AT, Carter EG.

Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82.


Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.

Chey WD, Lembo AJ, Rosenbaum DP.

Am J Gastroenterol. 2017 May;112(5):763-774. doi: 10.1038/ajg.2017.41. Epub 2017 Feb 28.


Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.

Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.

Supplemental Content

Support Center